← Leaderboards
Susan C Wright
Palo Alto Institute/Molecular Medicine
$6,435,962
Attributed
$6,435,962
Total exposure
23
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $583.3K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$6,435,962 · 23
By mechanism
R43$3,764,202 · 20
R44$1,942,162 · 2
R01$729,598 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cytokine”
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$83,965,880
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- Fulton T Crews · University Of North Carolina Chapel Hill$36,249,590
- Marianne Ward · Duke University$34,872,957
- Joren C Madsen · Massachusetts General Hospital$33,058,731
- Barton F Haynes · Duke University$29,068,807
Research focus
CytokineProductionLaboratory MouseMouse ModelFuturePre-ClinicalBaseLeadDrug Design /Synthesis /ProductionIn VivoTreatment EfficacyAnti-Inflammatory AgentsNovel TherapeuticsPharmaceutical PreparationsPublic Health RelevanceEvaluationAnti-InflammatoryCell LineMonitorPreparationAnimal ModelInflammationProteinsDrug Kinetics
Grant awards (28)
Novel Anti-inflammmatory Antibody Therapy for Inflammatory Bowel Disease$224,665
R43 · FY2016 · DK · contact PI
Neutralization of Fibrosis-promoting Marinobufagenin for Diabetic Nephropathy$224,779
R43 · FY2015 · DK · contact PI
Novel Hybrid Growth Factor for Immune Reconstitution in Sepsis$306,520
R43 · FY2014 · GM · contact PI
Novel Rho Kinase Inhibitor for Systemic Sclerosis$315,527
R43 · FY2013 · AR · contact PI
Novel Anti-fibrotic Therapy for Diabetic Nephropathy$267,743
R43 · FY2013 · DK · contact PI
A Novel Hybrid Multifunctional Cytokine for Immune Reconstitution$227,861
R43 · FY2012 · AI · contact PI
Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis$570,746
R44 · FY2011 · DK · contact PI
Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis$501,592
R44 · FY2010 · DK · contact PI
Novel Therapy for Pemphigus Vulgaris by Treatment with a Cholinergic Agonist$175,408
R43 · FY2009 · AR · contact PI
Novel Multiplex Assay for Biomarkers of Alzheimer's Disease$161,700
R43 · FY2009 · AG · contact PI
Novel Multiplex Assay for Sepsis Biomarkers$261,520
R43 · FY2008 · AI · contact PI
Multiplex Biomarkers for Prostate Cancer$198,821
R43 · FY2008 · CA · contact PI
Anti-inflammatory Nicotinic Agonists for Therapy of Ulcerative Colitis$103,300
R43 · FY2008 · DK · contact PI
Novel Multiplex Assay for Sepsis Biomarkers$281,400
R43 · FY2007 · AI · contact PI
Novel Multiplex Assay for Biomarkers of Obstructive Nephropathy$106,050
R43 · FY2007 · DK · contact PI
Novel Lipid Mobilizing Factor for Obesity$140,468
R43 · FY2005 · DK
Antibody Therapy Targeting a Novel Neuroblastoma Antigen$130,270
R43 · FY2005 · CA
Anti-Pseudomonas Biofilm Therapy for Cystic Fibrosis$100,000
R43 · FY2005 · AI
Small Molecule Inhibitor of Quorum Sensing$112,350
R43 · FY2004 · AI
Novel Immunotherapy for Hepatocellular Carcinoma$100,005
R43 · FY2004 · CA
Novel Therapy for Staphylococcal Infection$482,400
R44 · FY2002 · AI
MECHANISM OF NICOTINE INHIBITION OF APOPTOSIS$250,422
R01 · FY2002 · CA
Novel Therapy for Staphylococcal Infection$387,424
R44 · FY2001 · AI
MECHANISM OF NICOTINE INHIBITION OF APOPTOSIS$243,129
R01 · FY2001 · CA
Non-toxic Cancer Therapy$100,000
R43 · FY2001 · CA
MECHANISM OF NICOTINE INHIBITION OF APOPTOSIS$236,047
R01 · FY2000 · CA
NOVEL ANTI-BCL-2 DRUG FOR APOPTOSIS-RESISTANT CANCER$120,183
R43 · FY2000 · CA
NOVEL THERAPY FOR STAPHYLOCOCCAL INFECTION$105,632
R43 · FY2000 · AI